Home » Psychology news » FDA-approved Alzheimer’s drug lecanemab could prevent free-floating amyloid beta fibrils from damaging the brain
FDA-approved Alzheimer’s drug lecanemab could prevent free-floating amyloid beta fibrils from damaging the brain
May 10, 2023 by NewsBot
Researchers described the structure of a special type of amyloid beta plaque protein associated with Alzheimer's disease (AD) progression. Scientists showed the small aggregates of the amyloid beta protein could float through the brain tissue fluid, reaching many brain regions and disrupting local neuron functioning. The research also provided evidence that a newly approved AD treatment could neutralize these small, diffusible aggregates.